Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HCM HUTCHMED	$13.23 -1.3%	$14.12	$11.51 ▼ $21.50	$2.31B	0.55	100,602 shs	44,250 shs
IMVT Immunovant	$14.10 -1.3%	$15.15	$12.72 ▼ $34.47	$2.40B	0.75	1.22 million shs	1.43 million shs
MLTX MoonLake Immunotherapeutics	$38.17 -1.1%	$38.33	$31.42 ▼ $58.26	$2.44B	1.31	351,044 shs	221,888 shs
RCKT Rocket Pharmaceuticals	$2.48 +6.4%	$6.44	$2.19 ▼ $26.98	$264.83M	1.02	1.80 million shs	20.90 million shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HCM HUTCHMED	-1.34%	+0.08%	-12.27%	-20.44%	-30.91%
IMVT Immunovant	-1.33%	-2.15%	-8.56%	-30.37%	-50.39%
MLTX MoonLake Immunotherapeutics	-1.06%	-0.96%	-2.50%	-8.62%	-8.47%
RCKT Rocket Pharmaceuticals	+6.44%	-62.37%	-65.36%	-73.62%	-88.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HCM HUTCHMED	2.4534 of 5 stars	3.0	4.0	0.0	2.2	0.0	1.9
IMVT Immunovant	2.5061 of 5 stars	4.5	1.0	0.0	3.1	1.7	0.0
MLTX MoonLake Immunotherapeutics	3.1588 of 5 stars	4.5	2.0	0.0	3.4	2.5	0.0
RCKT Rocket Pharmaceuticals	4.9282 of 5 stars	4.4	3.0	4.7	3.1	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HCM HUTCHMED	2.00	Hold	$19.00	43.61% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	171.87% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$78.71	106.22% Upside
RCKT Rocket Pharmaceuticals	2.47	Hold	$22.46	805.71% Upside

Current Analyst Ratings Breakdown

Latest RCKT, MLTX, IMVT, and HCM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00
5/28/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$46.00 ➝ $17.00
5/28/2025	RCKT Rocket Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/27/2025	RCKT Rocket Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/19/2025	MLTX MoonLake Immunotherapeutics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$61.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HCM HUTCHMED	$630.20M	3.66	$0.54 per share	24.51	$4.27 per share	3.10
IMVT Immunovant	N/A	N/A	N/A	N/A	$2.08 per share	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$8.15 per share	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HCM HUTCHMED	$100.78M	N/A	0.00	9.06	N/A	N/A	N/A	N/A	6/18/2025 (Estimated)
IMVT Immunovant	-$259.34M	-$2.62	N/A	N/A	N/A	N/A	-77.94%	-69.82%	6/4/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$36.01M	-$2.30	N/A	N/A	N/A	N/A	-15.54%	-15.09%	8/6/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)

Latest RCKT, MLTX, IMVT, and HCM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/4/2025	Q4 2025	IMVT Immunovant	-$0.72	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HCM HUTCHMED	0.07	2.81	2.68
IMVT Immunovant	N/A	6.04	6.04
MLTX MoonLake Immunotherapeutics	N/A	25.51	25.51
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HCM HUTCHMED	8.82%
IMVT Immunovant	47.08%
MLTX MoonLake Immunotherapeutics	93.85%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
HCM HUTCHMED	3.60%
IMVT Immunovant	5.90%
MLTX MoonLake Immunotherapeutics	12.02%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HCM HUTCHMED	1,760	174.32 million	168.04 million	Not Optionable
IMVT Immunovant	120	169.86 million	159.84 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.22 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable

RCKT, MLTX, IMVT, and HCM Headlines

Recent News About These Companies

Bank of America Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $9.00

May 29 at 3:41 AM | americanbankingnews.com

Rocket Pharmaceuticals' (RCKT) "Hold" Rating Reiterated at Jefferies Financial Group

May 29 at 2:09 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Equal Weight Rating from Morgan Stanley

May 29 at 2:09 AM | americanbankingnews.com

Rocket Pharmaceuticals' (RCKT) Hold Rating Reiterated at Needham & Company LLC

May 29 at 1:37 AM | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Moderate Buy" from Brokerages

May 29 at 1:34 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

May 28 at 6:25 PM | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Connect

May 28 at 3:15 PM | accessnewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to "Hold" at TD Cowen

May 28 at 12:18 PM | marketbeat.com

RCKT Stock Tanks on Patient Death in Danon Disease Study

May 28 at 12:11 PM | zacks.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Lowered by Needham & Company LLC

May 28 at 11:29 AM | marketbeat.com

These Analysts Slash Their Forecasts On Rocket Pharmaceuticals

May 28 at 10:41 AM | benzinga.com

Rocket Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RCKT)

May 28 at 10:38 AM | marketbeat.com

US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease

May 28 at 5:39 AM | pharmabiz.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Receives "Hold" Rating from TD Cowen

May 28 at 2:41 AM | americanbankingnews.com

Investors Purchase High Volume of Rocket Pharmaceuticals Call Options (NASDAQ:RCKT)

May 28 at 1:06 AM | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death

May 27 at 9:28 PM | insidermonkey.com

Danon Disease Patient Dies in Rocket Gene Therapy Trial

May 27 at 7:37 PM | genengnews.com

Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold

May 27 at 12:00 PM | benzinga.com

Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient death

May 27 at 10:37 AM | proactiveinvestors.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 5.6% - Time to Sell?

May 25, 2025 | marketbeat.com

Woodline Partners LP Increases Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT, MLTX, IMVT, and HCM Company Descriptions

HUTCHMED NASDAQ:HCM

$13.23 -0.18 (-1.34%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$13.22 -0.01 (-0.08%)

As of 05/28/2025 04:04 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Immunovant NASDAQ:IMVT

$14.10 -0.19 (-1.33%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$14.41 +0.31 (+2.20%)

As of 04:50 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

MoonLake Immunotherapeutics NASDAQ:MLTX

$38.17 -0.41 (-1.06%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$38.18 +0.02 (+0.04%)

As of 05:21 AM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.48 +0.15 (+6.44%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$2.52 +0.04 (+1.57%)

As of 06:18 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time